Dyadic International to Announce First Quarter 2018 Financial Results and Host Conference Call on Thursday May 10, 2018
April 25 2018 - 4:30PM
JUPITER, Fla., April 25, 2018 (GLOBE NEWSWIRE) --
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 expression system to help speed up the development
and production of biologic vaccines and drugs at flexible
commercial scales, announced today that it will report its
financial results for the quarter ended March 31, 2018 after the
market close on Thursday, May 10, 2018 and that it will host a
conference call that day at 5:00 p.m. Eastern Time to discuss those
results.
In order to participate in the live session,
please use the following dial-in numbers five to ten minutes prior
to the start time:
Calling from the United States or Canada: 800-839-7875
Calling from other countries:
+ 719-325-4891
Confirmation Code: 7239777
A replay of the conference call will be
available on Dyadic’s website (www.dyadic.com) within 24 hours
after the live event.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila,
named C1. The C1 microorganism, which enables the development and
large scale manufacture of low cost proteins, has the potential to
be further developed into a safe and efficient expression system
that may help speed up the development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales. Dyadic is using the C1 technology and
other technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic pursues research
and development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of these technologies in
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic drugs to market faster, in greater volumes, at lower cost,
and with new properties to drug developers and manufacturers and,
hopefully, improve access and cost to patients and the healthcare
system, but most importantly save lives.
Please visit Dyadic’s website at www.dyadic.com
for additional information, including details regarding Dyadic’s
plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements involve risks, uncertainties and other factors that
could cause Dyadic’s actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements and are cautioned not
to place undue reliance on such forward-looking statements. Dyadic
expressly disclaims any intent or obligation to update or revise
any forward-looking statements to reflect actual results, any
changes in expectations or any change in events. Factors that could
cause results to differ materially include, but are not limited to:
(1) general economic, political and market conditions; (2) our
ability to carry out and implement our biopharmaceutical research
and business plans and strategic initiatives; (3) our ability to
retain and attract employees, consultants, directors and advisors;
(4) our ability to implement and successfully carry out Dyadic’s
and third parties research and development efforts; (5) our ability
to obtain new license and research agreements; (6) our ability to
maintain our existing access to, and/or expand access to third
party contract research organizations in order to carry out our
research projects for ourselves and third parties; (7) competitive
pressures and reliance on key customers and collaborators; and (8)
other factors discussed in Dyadic’s publicly available filings,
including information set forth under the caption “Risk Factors” in
our December 31, 2017 Annual Report filed with the OTC Markets on
March 27, 2018. New risks and uncertainties
arise from time to time, and it is impossible for us to predict
these events or how they may affect us.
Contact:
Dyadic International, Inc.
Mark A. Emalfarb
Chief Executive Officer
Phone: 561-743-8333
Email: memalfarb@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024